[go: up one dir, main page]

EP1806135A3 - The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation - Google Patents

The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation Download PDF

Info

Publication number
EP1806135A3
EP1806135A3 EP07004363A EP07004363A EP1806135A3 EP 1806135 A3 EP1806135 A3 EP 1806135A3 EP 07004363 A EP07004363 A EP 07004363A EP 07004363 A EP07004363 A EP 07004363A EP 1806135 A3 EP1806135 A3 EP 1806135A3
Authority
EP
European Patent Office
Prior art keywords
diabetic retinopathy
protein tyrosine
ocular inflammation
genistein
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07004363A
Other languages
German (de)
French (fr)
Other versions
EP1806135A2 (en
Inventor
Eugene Jr. ForSight Labs LLC De Juan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09041931 external-priority patent/US5919813C1/en
Priority claimed from US09/042,440 external-priority patent/US5980929A/en
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP1806135A2 publication Critical patent/EP1806135A2/en
Publication of EP1806135A3 publication Critical patent/EP1806135A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)

Abstract

The present invention is directed to a method for the prophylactic and therapeutic treatment of diabetic retinopathy and a method for the prophylactic and therapeutic treatment of ocular inflammation. The methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat diabetic retinopathy or ocular inflammation, respectively, prophylactically or therapeutically. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.
EP07004363A 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation Withdrawn EP1806135A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09041931 US5919813C1 (en) 1998-03-13 1998-03-13 Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US09/042,440 US5980929A (en) 1998-03-13 1998-03-13 Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
EP99911365A EP1061913B1 (en) 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP99911365.7 Division 1999-03-12
EP99911365A Division EP1061913B1 (en) 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy

Publications (2)

Publication Number Publication Date
EP1806135A2 EP1806135A2 (en) 2007-07-11
EP1806135A3 true EP1806135A3 (en) 2010-11-24

Family

ID=26718704

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07004363A Withdrawn EP1806135A3 (en) 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
EP99911365A Expired - Lifetime EP1061913B1 (en) 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99911365A Expired - Lifetime EP1061913B1 (en) 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy

Country Status (7)

Country Link
EP (2) EP1806135A3 (en)
JP (2) JP2002506028A (en)
AT (1) ATE365550T1 (en)
AU (1) AU756515B2 (en)
CA (1) CA2321560C (en)
DE (1) DE69936381T2 (en)
WO (1) WO1999045920A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE252387T1 (en) * 1998-11-23 2003-11-15 Novartis Pharma Gmbh USE OF STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF OCCULAR NEOVASCULAR DISEASES
WO2000037072A1 (en) * 1998-12-22 2000-06-29 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1178791A2 (en) * 1999-05-07 2002-02-13 Johns Hopkins University School of Medicine The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
ES2315598T3 (en) 1999-10-21 2009-04-01 Alcon, Inc. DEVICE FOR THE ADMINISTRATION OF PHARMACOS.
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
JP2003511204A (en) 1999-10-21 2003-03-25 アルコン，インコーポレイティド Tenon drug delivery
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
CA2388924A1 (en) * 1999-10-26 2001-05-03 Joan M. Robbins Ribozyme therapy for the treatment of proliferative skin and eye diseases
ES2271301T3 (en) 2001-07-23 2007-04-16 Alcon, Inc. FARMACO OFTALMICO SUPPLY DEVICE.
PT1409065E (en) 2001-07-23 2007-03-30 Alcon Inc Ophthalmic drug delivery device
JP2005515992A (en) * 2001-12-05 2005-06-02 ミトコー、インク Use of polycyclic phenolic compounds for the treatment of eye diseases
GB0302882D0 (en) * 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
US7642061B2 (en) 2003-05-02 2010-01-05 Centre National De La Recherche Scientifique Glut-1 as a receptor for HTLV envelopes and its uses
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050261197A1 (en) * 2004-05-19 2005-11-24 Henry Aoki Coffee bean extract, method of extraction and composition containing the same
CN104147005B (en) 2005-02-09 2018-07-03 参天制药株式会社 For treating the liquid preparation of disease or illness
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
EP2376917B1 (en) 2009-01-09 2016-03-30 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
WO2013126597A1 (en) * 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064101T3 (en) * 1990-04-02 1995-01-16 Pfizer THYROSINE KINASE INHIBITORS BENZYLPHOSPHONIC ACID COMPOUNDS.
CZ283965B6 (en) * 1992-08-06 1998-07-15 Warner-Lambert Company 2-thioindoles, 2-indolinethiones and polysulfides, their selenium analogs and pharmaceutical preparations based thereon
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAYASHI A ET AL: "Role of protein tyrosine phosphorylation in rat corneal neovascularization.", GRAEFES ARCH CLIN EXP OPHTHALMOL, JUL 1997, 235 (7) P460-7, July 1997 (1997-07-01), GERMANY, XP002113009 *
ROMERO J ET AL: "Pharmacologic modulation of acute ocular inflammation with quercetin.", OPHTHALMIC RES, 1989, 21 (2) P112-7, 1989, SWITZERLAND, XP002113010 *
SIMONELLI F ET AL: "OXIDATIVE STRESS IN OCULAR INFLAMMATION", CHIBRET INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, vol. 9, no. 3, 1 January 1993 (1993-01-01), pages 1 - 7, XP000607697, ISSN: 0748-9501 *

Also Published As

Publication number Publication date
WO1999045920A3 (en) 1999-10-21
ATE365550T1 (en) 2007-07-15
DE69936381D1 (en) 2007-08-09
AU3001999A (en) 1999-09-27
CA2321560C (en) 2007-05-22
EP1806135A2 (en) 2007-07-11
EP1061913B1 (en) 2007-06-27
JP2010168389A (en) 2010-08-05
EP1061913A2 (en) 2000-12-27
CA2321560A1 (en) 1999-09-16
DE69936381T2 (en) 2007-10-31
JP2002506028A (en) 2002-02-26
WO1999045920A2 (en) 1999-09-16
AU756515B2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
EP1806135A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
FR18C1012I2 (en) STAUROSPORINE DERIVATIVES INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY
BR0205722A (en) Prolonged release formulation and method for treating a patient suffering from pain
PT913156E (en) USE OF PROTEIN C ACTIVATED TO TREAT HYPERCERAGULATE STATES ASSOCIATED WITH SEPSIA
DK0799044T3 (en) Topical ophthalmological formulations containing olopatidine for the treatment of allergic eye diseases
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
NO20000446D0 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
AU3092397A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
BG105875A (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
BR0007452A (en) Use of melagatran or a pharmaceutically acceptable derivative or prodrug thereof, method of treating inflammation, and, pharmaceutical formulation for use in treating inflammation
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MXPA01011344A (en) The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.
BR0313503A (en) Restless Leg Syndrome Treatment Method, Adenoin a2a Receptor Antagonist Use, Therapeutic Agent for Restless Leg Syndrome, and Night Myoclonus Treatment Method
IE870577L (en) Topical amide preparation
MXPA03003980A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders.
MXPA01007952A (en) L-arginine based formulations for treating diseases and methods of using same.
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
NO984196L (en) Procedure for the treatment of substance abuse
AU2001273801A1 (en) Dehydrobaimuxinol derivatives use as medicaments for treating or preventing regressive diseases of brain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070302

AC Divisional application: reference to earlier application

Ref document number: 1061913

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/122 20060101ALI20100625BHEP

Ipc: A61K 31/352 20060101AFI20100625BHEP

Ipc: A61K 31/382 20060101ALI20100625BHEP

Ipc: A61K 31/00 20060101ALI20100625BHEP

Ipc: A61P 27/02 20060101ALI20100625BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20111209

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101ALI20130117BHEP

Ipc: A61P 27/02 20060101ALI20130117BHEP

Ipc: A61K 31/352 20060101AFI20130117BHEP

Ipc: A61K 31/382 20060101ALI20130117BHEP

Ipc: A61K 31/122 20060101ALI20130117BHEP

Ipc: A61K 31/395 20060101ALI20130117BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130611